Navigation Links
Kendle Appoints Martha Feller, PhD, Vice President and Global Head, Study Start-up
Date:2/28/2011

CINCINNATI, Feb. 28, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced Martha R. Feller, PhD, has rejoined the Company as Vice President and Global Head, Study Start-up, effective immediately. Dr. Feller brings to Kendle more than 30 years of senior operations leadership in the clinical development industry, including broad therapeutic expertise and vast experience in managing large-scale, multimillion-dollar global development programs. In her new role Dr. Feller will provide leadership for the Company's global Study Start-up function – including Study Start-up Management, Site Identification, Site Start-up, Clinical Trial Regulatory, Investigator Contracts and Essential Document Collection – and will focus on fostering strong site relationships to optimize timelines and deliver rapid study start-up for global clinical trials.

"Timely and efficient study start-up on global projects is essential to our business success and ability to deliver best-in-class clinical development solutions to our customers," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer. "The appointment of an experienced industry veteran to lead this important function demonstrates our commitment to delivery of site selection and start-up strategies that provide valuable time-saving results for our customers."

Dr. Feller rejoins Kendle following two years with i3 Research where she served as Executive Vice President, Global Operations responsible for Phase I-III clinical programs. From 2004 to 2009 Dr. Feller held leadership roles in Kendle's Phase II-III clinical development operations, serving most recently as Senior Vice President, Global Clinical Development. Prior to joining Kendle, she spent 24 years with Procter & Gamble Pharmaceuticals where she held several senior-level positions, including Associate Director, New Drug Development, responsible for leading the company's global development and regulatory approval efforts for a new female testosterone patch therapy and Associate Director, Worldwide Regulatory and Medical Affairs, OTC. Dr. Feller earned a Doctorate in biochemistry from the University of Cincinnati College of Medicine and a Bachelor of Science in chemistry and mathematics from Edgecliff College (now part of Xavier University).

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995. Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated study start-up efficiencies, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC.  All information in this press release is current as of Feb. 28, 2011. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO
2. Kendle to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. Kendle Announces Details Regarding Third Quarter 2010 Earnings Conference Call and Webcast
4. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
5. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
6. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
7. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
8. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
9. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
10. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
11. Kendle Launches New Global Biostatistics Infrastructure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)...   Risperdal lawsuits involving gynecomastia (male breast growth) ... of the atypical antipsychotic medication continue to move forward ... Common Pleas, where the state,s Risperdal docket has been ... notice posted on the Court,s website , the ... 9, 2017 at 11:00 a.m. (In Re: Risperdal Litigation, ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
(Date:2/17/2017)... , Feb. 17, 2017  BioDigital, Inc., ... the partnership of their 3D body mapping technology ... IT.  The new integration will be used to ... interactive model of the human body. BioDigital pilots ... clinicians time, while also increasing the precision of ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... Best ... an employee health benefit for companies that want to help members of their ... employees will have access to Watson’s suite of oncology offerings for insights on ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for ... joint event at Chuck E. Cheese’s locations throughout New England, New York and New ... opportunity to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be ... & Exposition, the event will take place February 23-25, 2017 at the Calvin L. ... in Booth #909 with three new ambulances on display. , “JEMS ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
Breaking Medicine News(10 mins):